Erratum: Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: A secondary analysis of a randomized clinical trial (JAMA Ophthalmology (2018) 136:3 (257-269) DOI: 10.1001/jamaophthalmol.2017.6565);Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment A secondary analysis of a randomized clinical trial

JAMA Ophthalmology

Volumn 136, Issue 3, 2018, Pages 257-269

  Bressler, Neil M ^a   Beaulieu, Wesley T ^b   Glassman, Adam R ^b   Blinder, Kevin J ^b,c   Bressler, Susan B ^a   Jampol, Lee M ^d   Melia, Michele ^b   Wells, John A ^e  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JAEB CENTER FOR HEALTH RESEARCH   (United States)

^c Retina Institute   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e Palmetto Retina Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; FUSION PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

ADULT; AGED; CLINICAL EXAMINATION; COMPARATIVE EFFECTIVENESS; CONFERENCE PAPER; DIABETIC MACULAR EDEMA; DISEASE COURSE; FEMALE; HUMAN; LOW LEVEL LASER THERAPY; MACULAR THICKNESS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT DURATION; VISUAL ACUITY; VISUAL IMPAIRMENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC RETINOPATHY; DIAGNOSTIC IMAGING; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MIDDLE AGED; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA LUTEA; VISUAL DISORDER;

AGED; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; DIABETIC RETINOPATHY; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULA LUTEA; MACULAR EDEMA; MALE; MIDDLE AGED; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISION DISORDERS; VISUAL ACUITY;

EID: 85043571510     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2018.0795     Document Type: Erratum

References (10)

1. Solomon SD, Chew E, Duh EJ, et al. Diabetic retinopathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40(3): 412-418.
2. Bressler SB, Ayala AR, Bressler NM, et al; Diabetic Retinopathy Clinical Research Network. Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment. JAMA Ophthalmol. 2016;134(3):278-285.
3. Elman MJ, Aiello LP, Beck RW, et al; Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064-1077.e35.
4. Wells JA, Glassman AR, Ayala AR, et al; Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193-1203.
5. Beck RW, Moke PS, Turpin AH, et al. A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol. Am J Ophthalmol. 2003;135(2):194-205.
6. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988;75 (4):800-802. doi:10.1093/biomet/75.4.800
7. Gonzalez VH, Campbell J, Holekamp NM, et al. Early and long-term responses to anti-vascular endothelial growth factor therapy in diabetic macular edema: analysis of Protocol I data. Am J Ophthalmol. 2016;172:72-79.
8. Ferris FL III, Maguire MG, Glassman AR, Ying G-s, Martin DF. Evaluating effects of switching anti-vascular endothelial growth factor drugs for age-related macular degeneration and diabetic macular edema. JAMA Ophthalmol. 2017;135(2): 145-149.
9. Maturi RK, Glassman AR, Liu D. Diabetic Retinopathy Clinical Research Network. Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR Network phase 2 randomized clinical trial [published online November 11, 2017. JAMA Ophthalmol. doi:10.1001/jamaophthalmol.2017.4914
10. Wells JA, Glassman AR, Ayala AR, et al; Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123(6):1351-1359.